Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05792111
Other study ID # AIBU-Med-MB-01
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date October 12, 2022
Est. completion date December 20, 2024

Study information

Verified date March 2023
Source Abant Izzet Baysal University
Contact murat bilgi, prof.dr
Phone +90505 374 50 59
Email drmuratbilgi@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This prospective randomized study will be conducted in Bolu Abant İzzet Baysal University Hospital. Chronic low back and hip pain 72 patients aged between 18-70 years will be included in the study. The primary output of our study was NRS scores. The study of Manchikanti. L et al. (control group NRS reduction 4.4 ± 1.8; α margin of error 0.05, power 99%) (3) was taken as the basis for determining the sample size. Using the G Power 3 calculator program, 72 patients were identified to reduce their NRS scores by 25%. With a 20% exclusion rate, the total number of patients was calculated as 90


Description:

Demographic information of all patients included in the study; name, surname, telephone number, age, gender, educational status, profession, and marital status will be recorded. The duration of the pain, the onset of the pain, the accompanying leg pain, the activities that increase or decrease the pain, the presence of neurological symptoms, the analgesic agents used in the last week, and the previous treatments will be noted. Lumbar MRI findings and the level of pathology causing low back and hip pain will be recorded. History, family history, comorbidities (hypertension, diabetes mellitus, hyperlipidemia, cardiac disease, hypothyroidism), and detailed physical examinations of the patients will be recorded. Examinations of the patients before and 3, 6, and 12 weeks after the injection will be performed, and NRS scores at 3 and 6 weeks. The procedures will be repeated for patients who are over 4 years old. During the pre-procedural evaluation, the patients will be informed about the study, information about the Numeric Rating Score (NRS), Oswestry Disability Index (ODI), Short Form-36 (SF-36) to be used for post-procedure analgesia, and both verbal and written consents will be obtained. The staff who will make the evaluation will not know which group the patients belong to, and the study will be blinded.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date December 20, 2024
Est. primary completion date December 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Low back or leg pain that has been going on for at least 2 months, - Patients between the ages of 18-70, - Disc herniation or radiculopathy in lumbar MRI examination .To be mentally competent to understand and evaluate NRS, ODI, and SF-36 forms. exclusion criteria - Being pregnant or lactating, - Presence of spinal canal stenosis, - The presence of bleeding diathesis, - Presence of disease with progressive neurological deficit, - The presence of serious psychiatric illness, - Presence of progressive neurological deficit or incontinence, - Having an epidural steroid injection in the last 6 months, Having uncontrolled diabetes mellitus Having hypertension, - Known history of allergy to local anesthetics or corticosteroids, - The patient does not want treatment, - Local infection at the injection site, - Infections such as discitis, spondylodiscitis, and sacroiliitis.

Study Design


Intervention

Drug:
Trigger point injection (lidocaine)
trigger point injection will be added to the gluteus medius and minimus muscles in addition to caudal epidural steroid injection.
Caudal epidural Group (bupivacaine + triamcinolone + NaCl)
It will be advanced towards the sacral hiatus and local anesthesia of the skin and subcutaneous tissue will be provided with 2% lidocaine. The caudal epidural space will be entered by puncturing the sacrococcygeal ligament with the tip of a 22 G black needle from the appropriate area and taking a pop sensation. It will be confirmed that there is no bleeding or cerebrospinal fluid in this area by applying saline in real-time sonography and after the caudal epidural spread is observed, aspiration is performed. Afterward, a 10 mL volume of bupivacaine 4cc/20mg+ triamcinolone 2cc/80mg+0.09% NaCl 4cc mixture will be administered into the caudal epidural space

Locations

Country Name City State
Turkey Abant Izzet Baysal University Medical School, Bolu

Sponsors (1)

Lead Sponsor Collaborator
Abant Izzet Baysal University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Numerical Rating Scale (NRS) score NRS score measures a patient's pain intensity. For example, (range 0-10) where 0 is no pain and 10 is the worst pain basaline,
Primary Numerical Rating Scale (NRS) score NRS score measures a patient's pain intensity. For example, (range 0-10) where 0 is no pain and 10 is the worst pain after ESI 3 weeks,
Primary Numerical Rating Scale (NRS) score NRS score measures a patient's pain intensity. For example, (range 0-10) where 0 is no pain and 10 is the worst pain after ESI 6 weeks
Primary Numerical Rating Scale (NRS) score NRS score measures a patient's pain intensity. For example, (range 0-10) where 0 is no pain and 10 is the worst pain after ESI12 weeks
Secondary Oswestry Disability Index used to qualify low back pain.(range 0 to 100).Zero is equated with no disability and 100 is the maximum disability possible basaline
Secondary Oswestry Disability Index used to qualify low back pain.(range 0 to 100).Zero is equated with no disability and 100 is the maximum disability possible after ESI 3 weeks
Secondary Oswestry Disability Index used to qualify low back pain.(range 0 to 100).Zero is equated with no disability and 100 is the maximum disability possible after ESI 6 weeks
Secondary Oswestry Disability Index used to qualify low back pain.(range 0 to 100).Zero is equated with no disability and 100 is the maximum disability possible after ESI12 weeks
Secondary Short Form-36 used to measure of patient's health status.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. basaline
Secondary Short Form-36 used to measure of patient's health status.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. after ESI 3 weeks,
Secondary Short Form-36 used to measure of patient's health status.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. ,after ESI 6 weeks
Secondary Short Form-36 used to measure of patient's health status.The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. after ESI12 weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06029413 - Myo vs. Myofascial Injection for Myofascial Trigger Points N/A
Recruiting NCT04985578 - Effects on Muscle Activity After Dry Needling in Myofascial Trigger Points of the Gastrocnemius Muscles N/A
Completed NCT05546203 - Trigger Point Treatment in Chronic Pelvic Pain N/A
Completed NCT06258070 - Clinical Performance of Therapeutic Use of BTX for Bruxism N/A
Completed NCT04531306 - An Analysis of Kinesio® Tape on Myofascial Pain Syndrome of the Iliotibial Band N/A
Completed NCT03708107 - Percutaneous Microelectrolysis (MEP) Versus Ischemic Compression in Miofascial Trigger Points N/A
Completed NCT02913976 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Patients Diagnosed With Cervical Pain N/A
Completed NCT02913963 - Changes on Pain and Range of Motion by the Use of Kinesio Taping in Subjects With Myofascial Trigger Point N/A
Completed NCT04719689 - Comparison of Dry Needling and Dry Cupping in Positional Fault of Pelvis N/A
Completed NCT03704311 - Evaluation of Mitochondrial Function in Myofascial Trigger Points Cohort Pilot Study Using High-resolution Respirometry N/A
Recruiting NCT05429827 - The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome N/A
Recruiting NCT05151510 - Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department Phase 4
Completed NCT05396196 - An Analysis of Kinesio® Tape With Manual Fascial Glide Application on Trigger Points in The Iliotibial Band N/A
Completed NCT05664165 - The Efficiency of Dry Needling and Cold Spray-stretching Treatments N/A
Completed NCT01250184 - Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. Phase 4
Enrolling by invitation NCT03941054 - Myosfascial Trigger-Points and Effects on Neuromuscular Response N/A
Completed NCT04993118 - Integration of Neuromuscular Inhibition Technique On Trapezius Trigger Points. N/A
Completed NCT04851743 - Effects on Neuromuscular Function After Dry Needling in Myofascial Trigger Points in the Gastrocnemius Muscles N/A
Not yet recruiting NCT06338514 - The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome. N/A
Recruiting NCT06013644 - Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome Early Phase 1